TY - JOUR T1 - Pharmacogenomics in Lung Cancer Chemotherapy: A Review of What the Oncologist Should Know JF - Anticancer Research JO - Anticancer Res SP - 5241 LP - 5250 VL - 34 IS - 10 AU - CHIARA D'ANTONIO AU - ANNALISA MILANO AU - RICCARDO RIGHINI AU - CONCETTA ELISA ONESTI AU - MARIA BASSANELLI AU - ROSA FALCONE AU - IDA PARIS AU - SALVATORE LAURO AU - PAOLO MARCHETTI Y1 - 2014/10/01 UR - http://ar.iiarjournals.org/content/34/10/5241.abstract N2 - Lung cancer is the leading cause of cancer-related death around the world; the addition of chemotherapy to treatment of this disease has been shown to significantly increase progression-free survival and overall survival. Despite newer chemotherapies, it is important to personalize the care (treatment and dose) upon each single patient's susceptibility for controlling and reducing adverse side-effects, at best. The present review describes the current status of pharmacogenomics studies regarding germline DNA variants that may alter response and tolerability to chemotherapeutic agents used to treat lung cancer, including perspective studies. ER -